National Toxicology Program

National Toxicology Program
https://ntp.niehs.nih.gov/go/4957

TDMS Study 88133-06 Pathology Tables

NTP Experiment-Test: 88133-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                          TRIMETHYLOLPROPANE TRIACRYLATE                              Date: 10/30/02
Route: SKIN APPLICATION                                                                                           Time: 10:04:53

                                                            Final#3




       Facility:  Battelle Columbus Laboratory

       Chemical CAS #:  15625-89-5

       Lock Date:  06/16/99

       Cage Range:  All

       Reasons For Removal:    All

       Removal Date Range:     All

       Treatment Groups:       Include 002    0 MG/KG
                               Include 001    0 MG/KG
                               Include 004    0.75    MG/KG
                               Include 003    0.75    MG/KG
                               Include 006    1.5     MG/KG
                               Include 005    1.5     MG/KG
                               Include 008    3 MG/KG
                               Include 007    3 MG/KG
                               Include 010    6 MG/KG
                               Include 009    6 MG/KG
                               Include 012    12 MG/KG
                               Include 011    12 MG/KG























a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 88133-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                          TRIMETHYLOLPROPANE TRIACRYLATE                              Date: 10/30/02  
Route: SKIN APPLICATION                                                                                           Time: 10:04:53  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         TGAC (FVB/N) HEMIZYGOUS FEMALE            0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          15           15           15           15           15           15           
  Early Deaths                                                                                                                      
    Natural Death                                                   1            2            1            1            3           
    Moribund Sacrifice                                                           1                                                  
  Survivors                                                                                                                         
    Terminal Sacrifice                                15           14           12           14           14           12           
                                                                                                                                    
  Animals Examined Microscopically                    15           15           15           15           15           15           
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Liver                                              (15)         (15)         (15)         (15)         (15)         (15)         
      Leukemia Erythrocytic                                         1 (7%)                    1 (7%)                    2 (13%)     
      Lymphoma Malignant                                                                                                1 (7%)      
   Salivary Glands                                    (1)                                                              (1)          
      Carcinoma                                        1 (100%)                                                                     
   Stomach, Forestomach                               (15)         (15)         (15)         (15)         (15)         (15)         
      Squamous Cell Papilloma                          3 (20%)      4 (27%)      3 (20%)      1 (7%)       4 (27%)      6 (40%)     
      Squamous Cell Papilloma, Multiple                1 (7%)       1 (7%)       1 (7%)       1 (7%)       1 (7%)       3 (20%)     
   Tooth                                              (1)          (4)          (3)          (1)          (3)          (2)          
      Odontogenic Tumor                                1 (100%)     4 (100%)     2 (67%)                   3 (100%)     1 (50%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (15)         (15)         (15)         (15)         (15)         (15)         
      Leukemia Erythrocytic                                                                                             1 (7%)      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Pituitary Gland                                    (15)         (15)         (15)         (15)         (15)         (15)         
      Leukemia Erythrocytic                                                                                             2 (13%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   2                                                               
                                                                                                                                   
NTP Experiment-Test: 88133-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                          TRIMETHYLOLPROPANE TRIACRYLATE                              Date: 10/30/02  
Route: SKIN APPLICATION                                                                                           Time: 10:04:53  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         TGAC (FVB/N) HEMIZYGOUS FEMALE            0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Ovary                                              (15)         (15)         (15)         (15)         (15)         (15)         
      Leukemia Erythrocytic                                                                                             1 (7%)      
   Uterus                                             (15)         (15)         (15)         (15)         (15)         (15)         
      Leukemia Erythrocytic                                                                                             1 (7%)      
   Vagina                                                          (1)                                                              
      Squamous Cell Papilloma                                       1 (100%)                                                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Lymph Node                                         (11)         (14)         (13)         (10)         (13)         (12)         
      Mediastinal, Leukemia Erythrocytic                                                                                2 (17%)     
   Lymph Node, Mandibular                             (15)         (15)         (15)         (15)         (15)         (15)         
      Leukemia Erythrocytic                                                                   1 (7%)                    1 (7%)      
   Lymph Node, Mesenteric                             (15)         (14)         (14)         (15)         (15)         (15)         
      Leukemia Erythrocytic                                                                                             2 (13%)     
   Spleen                                             (15)         (15)         (15)         (15)         (15)         (15)         
      Leukemia Erythrocytic                                         1 (7%)                    1 (7%)                    2 (13%)     
      Lymphoma Malignant                                                                                                1 (7%)      
   Thymus                                             (15)         (15)         (15)         (15)         (15)         (15)         
      Leukemia Erythrocytic                                                                                             2 (13%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (15)         (15)         (15)         (15)         (15)         (15)         
      Squamous Cell Papilloma                                       1 (7%)                    1 (7%)                                
      Skin, Site of Application, Leukemia                                                                                           
          Erythrocytic                                                                                                  2 (13%)     
      Skin, Site of Application, Squamous Cell                                                                                      
          Carcinoma                                                              1 (7%)                    1 (7%)       1 (7%)      
      Skin, Site of Application, Squamous Cell                                                                                      
          Papilloma                                                                           1 (7%)       6 (40%)                  
      Skin, Site of Application, Squamous Cell                                                                                      
          Papilloma, Multiple                                                                              5 (33%)     15 (100%)    
      Vulva, Squamous Cell Papilloma                                                                       1 (7%)                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   3                                                               
                                                                                                                                   
NTP Experiment-Test: 88133-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                          TRIMETHYLOLPROPANE TRIACRYLATE                              Date: 10/30/02  
Route: SKIN APPLICATION                                                                                           Time: 10:04:53  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         TGAC (FVB/N) HEMIZYGOUS FEMALE            0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   Bone                                                            (1)                                                              
      Osteosarcoma                                                  1 (100%)                                                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (15)         (15)         (15)         (15)         (15)         (15)         
      Alveolar/Bronchiolar Adenoma                     1 (7%)                                 1 (7%)                                
      Leukemia Erythrocytic                                                                   1 (7%)                    1 (7%)      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (15)         (15)         (15)         (15)         (15)         (15)         
      Leukemia Erythrocytic                                                                   1 (7%)                    1 (7%)      
      Lymphoma Malignant                                                                                                1 (7%)      
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(15)        *(15)        *(15)        *(15)        *(15)        *(15)         
      Leukemia Erythrocytic                                         1 (7%)                    1 (7%)                    2 (13%)     
      Lymphoma Malignant                                                                                                1 (7%)      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   4                                                               
                                                                                                                                   
NTP Experiment-Test: 88133-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                          TRIMETHYLOLPROPANE TRIACRYLATE                              Date: 10/30/02  
Route: SKIN APPLICATION                                                                                           Time: 10:04:53  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         TGAC (FVB/N) HEMIZYGOUS FEMALE            0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)             6           9           6           5          12          15               
     Total Primary Neoplasms                            7          13           7           6          21          29               
                                                                                                                                    
   Total Animals with Benign Neoplasms                  5           5           4           4          11          15               
     Total Benign Neoplasms                             5           7           4           5          17          24               
                                                                                                                                    
   Total Animals with Malignant Neoplasms               1           2           1           1           1           3               
     Total Malignant Neoplasms                          1           2           1           1           1           4               
                                                                                                                                    
   Total Animals with Metastatic Neoplasms                                                                                          
     Total Metastatic Neoplasm                                                                                                      
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                  1           4           2                       3           1               
     Total Uncertain Neoplasms                          1           4           2                       3           1               
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   5                                                               
                                                                                                                                   
NTP Experiment-Test: 88133-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                          TRIMETHYLOLPROPANE TRIACRYLATE                              Date: 10/30/02  
Route: SKIN APPLICATION                                                                                           Time: 10:04:53  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         TGAC (FVB/N) HEMIZYGOUS MALE              0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          15           15           15           15           15           15           
  Early Deaths                                                                                                                      
    Natural Death                                      1                         3            1            2            4           
  Survivors                                                                                                                         
    Terminal Sacrifice                                14           15           12           14           13           11           
                                                                                                                                    
  Animals Examined Microscopically                    15           15           15           15           15           15           
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Liver                                              (15)         (15)         (15)         (15)         (15)         (15)         
      Leukemia Erythrocytic                                                                                             1 (7%)      
      Lymphoma Malignant                                                                      1 (7%)                                
   Salivary Glands                                                              (1)          (1)                       (2)          
      Carcinoma                                                                  1 (100%)     1 (100%)                  1 (50%)     
   Stomach, Forestomach                               (15)         (15)         (15)         (15)         (15)         (15)         
      Squamous Cell Papilloma                          3 (20%)      4 (27%)      1 (7%)       2 (13%)      2 (13%)      2 (13%)     
      Squamous Cell Papilloma, Multiple                2 (13%)      3 (20%)                   2 (13%)      1 (7%)                   
   Tooth                                              (1)          (3)          (1)          (2)          (1)          (1)          
      Odontogenic Tumor                                1 (100%)     3 (100%)     1 (100%)                  1 (100%)     1 (100%)    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (15)         (15)         (15)         (15)         (15)         (15)         
      Lymphoma Malignant                                                                      1 (7%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Pituitary Gland                                    (15)         (15)         (15)         (14)         (15)         (15)         
      Lymphoma Malignant                                                                      1 (7%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   6                                                               
                                                                                                                                   
NTP Experiment-Test: 88133-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                          TRIMETHYLOLPROPANE TRIACRYLATE                              Date: 10/30/02  
Route: SKIN APPLICATION                                                                                           Time: 10:04:53  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         TGAC (FVB/N) HEMIZYGOUS MALE              0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Lymph Node                                         (13)         (13)         (14)         (15)         (14)         (14)         
      Mediastinal, Lymphoma Malignant                                                         1 (7%)                                
   Lymph Node, Mandibular                             (15)         (14)         (15)         (15)         (14)         (13)         
      Leukemia Erythrocytic                                                                                             1 (8%)      
      Lymphoma Malignant                                                                      1 (7%)                                
   Lymph Node, Mesenteric                             (15)         (14)         (14)         (15)         (15)         (12)         
      Leukemia Erythrocytic                                                                                             1 (8%)      
      Lymphoma Malignant                                                                      1 (7%)                                
   Spleen                                             (15)         (15)         (15)         (15)         (15)         (15)         
      Leukemia Erythrocytic                                                                                             1 (7%)      
      Lymphoma Malignant                                                                      1 (7%)                                
   Thymus                                             (15)         (15)         (14)         (15)         (15)         (15)         
      Lymphoma Malignant                                                                      1 (7%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (15)         (15)         (15)         (15)         (15)         (15)         
      Squamous Cell Papilloma                                                                                           2 (13%)     
      Skin, Site of Application, Squamous Cell                                                                                      
          Papilloma                                                                           2 (13%)                               
      Skin, Site of Application, Squamous Cell                                                                                      
          Papilloma, Multiple                                                                             12 (80%)     13 (87%)     
      Subcutaneous Tissue, Fibrosarcoma                                          1 (7%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   7                                                               
                                                                                                                                   
NTP Experiment-Test: 88133-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                          TRIMETHYLOLPROPANE TRIACRYLATE                              Date: 10/30/02  
Route: SKIN APPLICATION                                                                                           Time: 10:04:53  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         TGAC (FVB/N) HEMIZYGOUS MALE              0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (15)         (15)         (15)         (15)         (15)         (14)         
      Lymphoma Malignant                                                                      1 (7%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (15)         (15)         (15)         (15)         (15)         (15)         
      Lymphoma Malignant                                                                      1 (7%)                                
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(15)        *(15)        *(15)        *(15)        *(15)        *(15)         
      Leukemia Erythrocytic                                                                                             1 (7%)      
      Lymphoma Malignant                                                                      1 (7%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   8                                                               
                                                                                                                                   
NTP Experiment-Test: 88133-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                          TRIMETHYLOLPROPANE TRIACRYLATE                              Date: 10/30/02  
Route: SKIN APPLICATION                                                                                           Time: 10:04:53  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         TGAC (FVB/N) HEMIZYGOUS MALE              0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)             6           8           4           6          12          13               
     Total Primary Neoplasms                            6          10           4           8          16          20               
                                                                                                                                    
   Total Animals with Benign Neoplasms                  5           7           1           5          12          13               
     Total Benign Neoplasms                             5           7           1           6          15          17               
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                       2           1                       2               
     Total Malignant Neoplasms                                                  2           2                       2               
                                                                                                                                    
   Total Animals with Metastatic Neoplasms                                                                                          
     Total Metastatic Neoplasm                                                                                                      
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                  1           3           1                       1           1               
     Total Uncertain Neoplasms                          1           3           1                       1           1               
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   9                                                               
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------                                           
NTP is located at the National Institute of Environmental Health Sciences, part of the National Institutes of Health.